Skip to main content

News Releases & Statements

News Releases & Statements

FDA Approves Isatuximab for Relapsed/Refractory Multiple Myeloma

Rye Brook, N.Y., April 20, 2021 - The U.S. Food and Drug Administration (FDA) approved isatuximab (Sarclisa) in combination with carfilzomib and dexamethasone to treat adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.

Read More
Everyday

Everyday Heroes Fight for a Cancer-Free Future

Rye Brook, NY (April 15, 2021) Every three minutes, one person in the U.S. is diagnosed with a blood cancer. But, The Leukemia & Lymphoma Society (LLS), the global leader in the fight against blood cancer, is making game-changing progress in changing this statistic. Read More

New Report: Patients Pay the Price with Proliferation of Substandard Health Plans

WASHINGTON, D.C., March 25, 2021 – A new report published by 30 patient organizations shows the significant risks patients face when they enroll in non-compliant and substandard health insurance products, and details ways state and federal lawmakers can help protect these vulnerable consumers.

Read More

New Survey Reveals COVID-19 Vaccine Hesitancy Among Those with Cancer Diagnosis

RYE BROOK, N.Y., March 8, 2021 - A new survey of more than 6,500 U.S. blood cancer patients and survivors reveals that only half are very likely to get a COVID-19 vaccine while one in three is either unlikely or unsure about it. The nationwide survey was a collaboration between The Leukemia & Lymphoma Society (LLS), Boston University Questrom School of Business and The Behaviouralist, a London-based research consultancy.

Read More
LLS

LLS Statement on Inauguration Day 2021

February 18, 2021, Our right to vote is the heart of our democracy, as is a free and fair election. The democratic process is critical to our work at The Leukemia & Lymphoma Society where civic engagement is a cornerstone of our values. Every day, LLS works directly with lawmakers at the state and federal levels to advance policies that serve the best interests of blood cancer patients. Every member of the LLS community – staff, donors and volunteers – works tirelessly to make our communities and our country a better place. That work will never stop.

Read More

New Drug Approval Expands Options for Patients with Rare Marginal Zone Lymphoma and Advanced Follicular Lymphoma

Rye Brook, N.Y. February 5, 2021 – The U.S. Food and Drug Administration (FDA) today announced approval of UKONIQ™ (umbralisib), a once-daily, oral medication for the treatment of marginal zone lymphoma (MZL) that has returned or worsened following prior treatment with an anti-CD20 antibody. MZL is a clinical heterogeneous, slow-growing non-hodgkin lymphoma composed of three subtypes: extranodal, nodal or splenic MZL. It is considered a slow growing disease with generally favorable outcome. Read More

FDA Approval of New CAR T-Cell Therapy Further Solidifies Immunotherapy as a Mainstay in Cancer Treatment

Rye Brook, N.Y. February 5, 2021 -- The U.S. Food and Drug Administration (FDA) today announced approval of a new CAR T-cell treatment for adult patients with certain forms of relapsed/refractory large B-cell lymphoma. With this latest approval, there are now four FDA-approved CAR T-cell therapies, and what was a brand-new approach introduced just three years ago, today is a mainstay in cancer care with scores of children and adults who were near death now in long-lasting remissions.

Read More
Burlington

Burlington Stores & its Customers Raise Nearly $4 Million for The Leukemia & Lymphoma Society (LLS) in the Fight Against Blood Cancer

RYE BROOK, NY, February 10, 2021  – The Leukemia & Lymphoma Society (LLS), the global leader in the fight against blood cancer, and Burlington Stores, the national retailer delivering amazing deals to customers every time they shop, teamed up for the 19th consecutive year to raise critical funds to support LLS’s goal of creating a world without blood cancer, and to further their LLS Children’s Initiative, a multi-year endeavor LLS is set ou Read More

Media Requests

Please send all media-related inquiries and interview requests to mediarelations@lls.org.  An LLS representative will respond as soon as possible.